Acadian Asset Management
OCUL icon

Acadian Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Acadian Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,687
Closed -$32K – 2189
2025
Q4 		$32K Buy
+2,687
New +$32.6K ﹤0.01% 1850
2024
Q4 		– Sell
-8,142
Closed -$70K – 2015
2024
Q3 		$70K Buy
+8,142
New +$67.1K ﹤0.01% 1713
2024
Q2 		– Sell
-2,536
Closed -$23K – 1867
2024
Q1 		$23K Buy
+2,536
New +$18K ﹤0.01% 1473
2016
Q3 		– Sell
-85,259
Closed -$422K – 1514
2016
Q2 		$422K Buy
+85,259
New +$845K ﹤0.01% 801

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acadian Asset Management's OCUL Position: Q1 2026 in Review

Acadian Asset Management sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 2,687 shares — an estimated $32K sold.

Acadian Asset Management first reported a position in OCUL in Q2 2016 and held it in 4 quarters. The position peaked at $422K in Q2 2016. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Acadian Asset Management reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 2,687 Ocular Therapeutix shares in Q1 2026, an estimated $32K.
  • Acadian Asset Management first reported a position in Ocular Therapeutix in Q2 2016 and held it in 4 quarters.
  • Acadian Asset Management's Ocular Therapeutix position peaked at $422K in Q2 2016.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.